GlobeNewsWire
11 Feb 2026, 23:27 UTC · 31w ago
Verdict
Headline takes no side. We score MSB +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Mesoblast is launching a pivotal trial this quarter to seek a label extension of Ryoncil® for adults with severe SR-aGvHD.
More positive than 99% of claims this week
EIND program data showed that adult patients had survival outcomes at least as favorable as children receiving Ryoncil®.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 92% of claims this week
Data indicates a significantly higher mortality rate (15%) for patients receiving Ryoncil® as third-line treatment compared to second-line (2%).
More positive than 63% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company reported positive survival outcomes for Ryoncil and is initiating a pivotal trial for adult label extension.
More positive than 86% of ticker scores this week
The company reported positive survival outcomes for Ryoncil and is initiating a pivotal trial for adult label extension.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
8h ago
−41.5%
Price is moving against the score
$20.17 vs $34.49 close before publication (Feb 11) · not market-adjusted
MSB chart →
